# Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

> **NCT01121939** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 43 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Pertuzumab
- **DRUG:** Sandostatin LAR® Depot

## Key facts

- **NCT ID:** NCT01121939
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-08
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2016-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121939, "Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01121939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*